This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bednar, M. M. Articles by Gross, C. E. Search for Related Content PubMed PubMed Citation Articles by Bednar, M. M. Articles by Gross, C. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Blood Thinners Related Collections Acute Stroke Syndromes Antiplatelets

(Stroke. 1999;30:887-893.)
© 1999 American Heart Association, Inc.

Comments, Opinions, and Reviews

Antiplatelet Therapy in Acute Cerebral Ischemia

Martin M. Bednar, MD, PhD Cordell E. Gross, MD

From the Divisions of Neurosurgery and Surgical Research and the Department of Pharmacology, University of Vermont, Burlington, VT 05405.

Correspondence to Martin M. Bednar, MD, PhD, Associate Professor, Neurosurgery and Pharmacology, Director, Division of Surgical Research, Division of Neurological Surgery, Given D 319, University of Vermont, Burlington, VT 05405. E-mail mbednar{at}zoo.uvm.edu

Background—Improved recognition of stroke signs and symptoms has paralleled the development of pharmacological strategies that may be examined to reduce stroke mortality and morbidity. Presently, tissue plasminogen activator is the only therapy that significantly improves outcome in acute stroke, with no agent demonstrating a significant reduction in mortality.

Summary of Review—Antiplatelet agents are a heterogenous class of drugs that have been successfully used for more than 2 decades in secondary stroke prevention. These agents include aspirin, with or without dipyridamole, and more recently, the adenosine antagonists ticlopidine and clopidogrel. However, studies of the use of antiplatelet agents within 48 hours of the ictus have examined only aspirin. Only 1 study, the Multicentre Acute Stroke Trial–Italy (MAST-I), entered patients within 6 hours of the ictus. These data suggest that an improvement in mortality may be related to the speed of administration. No significant adverse events were noted with early antiplatelet monotherapy. However, MAST-I did note a significant increase in early mortality in patients receiving aspirin plus streptokinase, a finding not adequately explained by an increase in the intracranial hemorrhage rate.

Conclusions—The use of antiplatelet therapy in acute stroke, clinical or experimental, has only recently received attention. It is likely that the use of antiplatelet agents for acute stroke therapy will be less restrictive than that currently seen for thrombolytics. Future studies should include an examination of those agents that have previously demonstrated efficacy in secondary stroke prevention, most notably, aspirin. The recognition that all platelet stimuli share a final common pathway that is dependent on the surface glycoprotein IIb/IIIa (fibrinogen) receptor has resulted in the development of various agents which block this receptor and are currently the focus for clinical trials. The role of nitric oxide in stroke therapy will depend on minimizing the hypotensive side effects of this agent. Stroke models are needed to provide preliminary data on the efficacy of antiplatelet therapy, especially as relates to the interaction of antiplatelet agents with thrombolytics.

Key Words: antiplatelet therapy • aspirin • cerebral infarction • stroke, acute

This article has been cited by other articles:

				F. Honda, H. Imai, M. Ishikawa, C. Kubota, T. Shimizu, M. Fukunaga, and N. Saito Cilostazol Attenuates Gray and White Matter Damage in a Rodent Model of Focal Cerebral Ischemia Stroke, January 1, 2006; 37(1): 223 - 228. [Abstract] [Full Text] [PDF]

				C.D. Garlichs, S. Kozina, S. Fateh-Moghadam, B. Tomandl, C. Stumpf, S. Eskafi, D. Raaz, A. Schmeisser, A. Yilmaz, J. Ludwig, et al. Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia Stroke, June 1, 2003; 34(6): 1412 - 1418. [Abstract] [Full Text] [PDF]

				T. Brott and J. Bogousslavsky Treatment of Acute Ischemic Stroke N. Engl. J. Med., September 7, 2000; 343(10): 710 - 722. [Full Text] [PDF]

				Z. Chen, P. Sandercock, H. Pan, C. Counsell, R. Collins, L. Liu, J. Xie, C. Warlow, and R. Peto Indications for Early Aspirin Use in Acute Ischemic Stroke : A Combined Analysis of 40 000 Randomized Patients From the Chinese Acute Stroke Trial and the International Stroke Trial Stroke, June 1, 2000; 31(6): 1240 - 1249. [Abstract] [Full Text] [PDF]

				V. B. Reddy, K. Kounga, F. Mariano, and E. A. Lerner Chrysoptin Is a Potent Glycoprotein IIb/IIIa Fibrinogen Receptor Antagonist Present in Salivary Gland Extracts of the Deerfly J. Biol. Chem., May 19, 2000; 275(21): 15861 - 15867. [Abstract] [Full Text] [PDF]

				Measuring and Improving Quality of Care : A Report From the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke Stroke, April 1, 2000; 31(4): 1002 - 1012. [Full Text] [PDF]

				Measuring and Improving Quality of Care : A Report From the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke Circulation, March 28, 2000; 101(12): 1483 - 1493. [Full Text] [PDF]

				J. Yrjanheikki, T. Tikka, R. Keinanen, G. Goldsteins, P. H. Chan, and J. Koistinaho A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window PNAS, November 9, 1999; 96(23): 13496 - 13500. [Abstract] [Full Text] [PDF]

				P. Sandercock, C. Warlow, M. Dennis, Z. M. Chen, M. M. Bednar, and C. E. Gross Antiplatelet Therapy in Acute Cerebral Ischaemia • Response Stroke, October 1, 1999; 30 (10): 2238k - 2248. [Full Text] [PDF]